adenine and Hepatitis C
adenine has been researched along with Hepatitis C in 44 studies
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 5.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
"Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients." | 5.39 | Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013) |
"Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time." | 5.33 | Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005) |
" Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1." | 4.87 | Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011) |
" Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)." | 4.82 | [Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003) |
" We also found that co-infection with HCV and treatment by the antiretrovirat drug Tenofovir are significantly associated with the decline in renal function among our patients [p=0." | 3.79 | [Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital]. ( Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E, 2013) |
" In multivariate analysis, renal dysfunction was associated with older age, non-Hispanic white race/ethnicity, higher body mass index (BMI), hypertension, higher cystatin C levels, and current prescription of ritonavir." | 3.78 | Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. ( Brooks, JT; Bush, T; Conley, L; Hammer, J; Henry, K; Kojic, EM; Mondy, K; Overton, ET; Patel, P; Rhame, F, 2012) |
" Treatment naive chronic hepatitis C patients should initially receive pegylated interferon and ribavirin dual combination therapy." | 3.78 | [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. ( Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E, 2012) |
"We reported previously that octadecyloxyethyl 9-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]adenine (ODE-(S)-HPMPA) was active against genotype 1b and 2a hepatitis C virus (HCV) replicons." | 3.77 | Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. ( Beadle, JR; Hostetler, KY; Hwu, JB; Prichard, MN; Schooley, RT; Valiaeva, N; Wyles, DL, 2011) |
"The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir." | 2.78 | Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. ( Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013) |
" Pharmacokinetic sampling was performed on days 1 through 4 and 22 through 25." | 2.72 | Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. ( Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S, 2006) |
"Five lamivudine patients were switched to tenofovir and in another one adefovir dipivoxil were added." | 2.46 | Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. ( Christodoulou, DK; Katsanos, KH; Tsianos, EV; Tsianos, VE; Vagias, I; Zervou, E; Zioga, H; Zois, CD, 2010) |
"Hepatitis A is an acute disease, while patients infected by hepatitis B and hepatitis C viruses are likely to develop chronical infections and severe complications (cancer, cirrhosis)." | 2.44 | [The ABC of viral hepatitis]. ( Van Bambeke, F, 2008) |
"Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 1.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
"Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients." | 1.39 | Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013) |
"Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce." | 1.36 | Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010) |
"Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time." | 1.33 | Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005) |
"03 mg/kg, which was approximately 100-fold more potent than that of Imiquimod, and showed an excellent oral bioavailability (F=40%) which was 10-fold improved over 5, a lead compound (F=4%)." | 1.32 | Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. ( Hirota, K; Ichii, S; Isobe, Y; Kawakami, H; Kurimoto, A; Ogino, T; Ogita, H; Sajiki, H; Takaku, H; Tobe, M, 2004) |
Research
Studies (44)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (4.55) | 18.2507 |
2000's | 16 (36.36) | 29.6817 |
2010's | 23 (52.27) | 24.3611 |
2020's | 3 (6.82) | 2.80 |
Authors
Authors | Studies |
---|---|
Yang, T | 1 |
Oliyai, R | 1 |
Kent, KM | 1 |
Huhn, GD | 1 |
Ramgopal, M | 1 |
Jain, MK | 1 |
Hinestrosa, F | 1 |
Asmuth, DM | 1 |
Slim, J | 1 |
Goldstein, D | 1 |
Applin, S | 1 |
Ryu, JH | 1 |
Jiang, S | 1 |
Cox, S | 1 |
Das, M | 1 |
Nguyen-Cleary, T | 1 |
Piontkowsky, D | 1 |
Guyer, B | 1 |
Rossaro, L | 1 |
Haubrich, RH | 1 |
Kim, GW | 1 |
Imam, H | 1 |
Khan, M | 1 |
Siddiqui, A | 1 |
MacBrayne, CE | 1 |
Marks, KM | 1 |
Fierer, DS | 1 |
Naggie, S | 1 |
Chung, RT | 1 |
Hughes, MD | 1 |
Kim, AY | 1 |
Peters, MG | 1 |
Brainard, DM | 1 |
Seifert, SM | 1 |
Castillo-Mancilla, JR | 1 |
Bushman, LR | 1 |
Anderson, PL | 1 |
Kiser, JJ | 1 |
Alsunaid, SR | 1 |
Ashraf, H | 1 |
Soubani, AO | 1 |
Núñez, M | 1 |
Mendes-Correa, MC | 1 |
Shahar, E | 1 |
Mugrabi, F | 1 |
Kedem, E | 1 |
Hassoun, G | 1 |
Pollack, S | 1 |
Gulland, A | 1 |
Bifano, M | 1 |
Hwang, C | 1 |
Oosterhuis, B | 1 |
Hartstra, J | 1 |
Grasela, D | 1 |
Tiessen, R | 1 |
Velinova-Donga, M | 1 |
Kandoussi, H | 1 |
Sevinsky, H | 1 |
Bertz, R | 1 |
Gervasoni, C | 1 |
Milazzo, L | 1 |
Pezzani, D | 1 |
Fucile, S | 1 |
Cattaneo, D | 1 |
Sagnelli, E | 1 |
Pisaturo, M | 1 |
Martini, S | 1 |
Sagnelli, C | 1 |
Filippini, P | 1 |
Coppola, N | 1 |
Sabo, JP | 1 |
Kort, J | 1 |
Ballow, C | 1 |
Haschke, M | 1 |
Battegay, M | 1 |
Fuhr, R | 1 |
Girlich, B | 1 |
Schobelock, M | 1 |
Feifel, U | 1 |
Lang, B | 1 |
Li, Y | 1 |
Elgadi, M | 1 |
Thong, VD | 1 |
Wasitthankasem, R | 1 |
Tangkijvanich, P | 1 |
Vongpunsawad, S | 1 |
Poovorawan, Y | 1 |
Renou, C | 1 |
Cadranel, JF | 1 |
Pariente, A | 1 |
Pénaranda, G | 1 |
Bourlière, M | 1 |
Halfon, P | 1 |
Igual, JP | 1 |
Harafa, A | 1 |
Muller, P | 1 |
Bertrand, JJ | 1 |
Laugier, R | 1 |
Laurent, C | 1 |
Bourgeois, A | 1 |
Mpoudi-Ngolé, E | 1 |
Kouanfack, C | 1 |
Ciaffi, L | 1 |
Nkoué, N | 1 |
Mougnutou, R | 1 |
Calmy, A | 1 |
Koulla-Shiro, S | 1 |
Ducos, J | 1 |
Delaporte, E | 1 |
Benson, N | 1 |
de Jongh, J | 1 |
Duckworth, JD | 1 |
Jones, HM | 1 |
Pertinez, HE | 1 |
Rawal, JK | 1 |
van Steeg, TJ | 1 |
Van der Graaf, PH | 1 |
Boyd, A | 1 |
Lasnier, E | 1 |
Molina, JM | 1 |
Lascoux-Combe, C | 1 |
Bonnard, P | 1 |
Miailhes, P | 1 |
Wendum, D | 1 |
Meynard, JL | 1 |
Girard, PM | 1 |
Lacombe, K | 1 |
Katsanos, KH | 1 |
Tsianos, VE | 1 |
Zois, CD | 1 |
Zioga, H | 1 |
Vagias, I | 1 |
Zervou, E | 1 |
Christodoulou, DK | 1 |
Tsianos, EV | 1 |
Mallet, V | 1 |
Vallet-Pichard, A | 1 |
Pol, S | 1 |
Overton, ET | 1 |
Patel, P | 1 |
Mondy, K | 1 |
Bush, T | 1 |
Conley, L | 1 |
Rhame, F | 1 |
Kojic, EM | 1 |
Hammer, J | 1 |
Henry, K | 1 |
Brooks, JT | 1 |
Valiaeva, N | 1 |
Wyles, DL | 1 |
Schooley, RT | 1 |
Hwu, JB | 1 |
Beadle, JR | 1 |
Prichard, MN | 1 |
Hostetler, KY | 1 |
Razonable, RR | 1 |
Makara, M | 1 |
Horváth, G | 1 |
Gervain, J | 1 |
Pár, A | 1 |
Szalay, F | 1 |
Telegdy, L | 1 |
Tornai, I | 1 |
Ujhelyi, E | 1 |
Hunyady, B | 1 |
Kalayjian, RC | 1 |
Lau, B | 1 |
Mechekano, RN | 1 |
Crane, HM | 1 |
Rodriguez, B | 1 |
Salata, RA | 1 |
Krishnasami, Z | 1 |
Willig, JH | 1 |
Martin, JN | 1 |
Moore, RD | 1 |
Eron, JJ | 1 |
Kitahata, MM | 1 |
Borghi, V | 1 |
Bisi, L | 1 |
Manzini, L | 1 |
Cossarizza, A | 1 |
Mussini, C | 1 |
Coffin, CS | 1 |
Fung, SK | 1 |
Ma, MM | 1 |
Ingiliz, P | 1 |
Patrick, I | 1 |
Krznaric, I | 1 |
Ivanka, K | 1 |
Obermeier, M | 1 |
Martin, O | 1 |
Prescott, LM | 1 |
Hirota, K | 2 |
Kazaoka, K | 1 |
Sajiki, H | 2 |
Maier, KP | 1 |
Hochman, JA | 1 |
Balistreri, WF | 1 |
Kurimoto, A | 1 |
Ogino, T | 1 |
Ichii, S | 1 |
Isobe, Y | 1 |
Tobe, M | 1 |
Ogita, H | 1 |
Takaku, H | 1 |
Kawakami, H | 1 |
Mauss, S | 1 |
Sterling, RK | 1 |
Sulkowski, MS | 1 |
Bárcena, R | 1 |
Del Campo, S | 1 |
Moraleda, G | 1 |
Casanovas, T | 1 |
Prieto, M | 1 |
Buti, M | 1 |
Moreno, JM | 1 |
Cuervas, V | 1 |
Fraga, E | 1 |
De la Mata, M | 1 |
Otero, A | 1 |
Delgado, M | 1 |
Loinaz, C | 1 |
Barrios, C | 1 |
Dieguez, ML | 1 |
Mas, A | 1 |
Sousa, JM | 1 |
Herrero, JI | 1 |
Muñoz, R | 1 |
Avilés, JF | 1 |
Gonzalez, A | 1 |
Rueda, M | 1 |
Lee, J | 1 |
Wu, CC | 1 |
Lee, KJ | 1 |
Chuang, TH | 1 |
Katakura, K | 1 |
Liu, YT | 1 |
Chan, M | 1 |
Tawatao, R | 1 |
Chung, M | 1 |
Shen, C | 1 |
Cottam, HB | 1 |
Lai, MM | 1 |
Raz, E | 1 |
Carson, DA | 1 |
Ramanathan, S | 1 |
Cheng, A | 1 |
Mittan, A | 1 |
Ebrahimi, R | 1 |
Kearney, BP | 1 |
Iino, S | 1 |
Yotsuyanagi, H | 2 |
Koike, K | 2 |
Van Bambeke, F | 1 |
Nakajima, N | 1 |
Hanaki, K | 1 |
Shimizu, YK | 1 |
Ohnishi, S | 1 |
Gunji, T | 1 |
Nakajima, A | 1 |
Nozaki, C | 1 |
Mizuno, K | 1 |
Odawara, T | 1 |
Yoshikura, H | 1 |
Pontisso, P | 1 |
Belluco, C | 1 |
Bertorelle, R | 1 |
De Moliner, L | 1 |
Chieco-Bianchi, L | 1 |
Nitti, D | 1 |
Lise, M | 1 |
Alberti, A | 1 |
Sponseller, CA | 1 |
Ramrakhiani, S | 1 |
Clinical Trials (3)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid[NCT02707601] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-01 | Completed | ||
Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)[NCT00146419] | 699 participants (Actual) | Observational | 2004-03-31 | Completed | |||
An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin[NCT00100581] | 2 participants (Actual) | Interventional | Completed | ||||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment
(NCT02707601)
Timeframe: Up to 32 weeks plus 30 days
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 62.5 |
F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20) | 69.4 |
E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12) | 83.8 |
F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12) | 79.7 |
Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)
Sustained Virologic Response (SVR12) was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 12
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF + LDV/SOF | 98.6 |
F/R/TAF + LDV/SOF | 95.8 |
Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)
SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 4
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF + LDV/SOF | 98.6 |
F/R/TAF + LDV/SOF | 98.6 |
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02707601)
Timeframe: 24 weeks after start of HIV treatment
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF + LDV/SOF | 1.4 |
F/R/TAF + LDV/SOF | 1.4 |
Reviews
13 reviews available for adenine and Hepatitis C
Article | Year |
---|---|
Viral hepatitis and HIV: update and management.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combina | 2013 |
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus; | 2014 |
Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy | 2010 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitab | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; | 2011 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S | 2003 |
Chronic viral hepatitis: always be current!
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis B; Hepatitis B v | 2003 |
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Ch | 2004 |
[Drugs for hepatitis B and C infection].
Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepat | 2007 |
[Mechanisms of drug resistance in hepatitis viruses B and C].
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Guanine; Hepacivirus; Hepatit | 2007 |
Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepacivirus; Hepatitis B; Hepatitis B vi | 2007 |
[The ABC of viral hepatitis].
Topics: Adenine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; I | 2008 |
Treatment of hepatitis B and C following liver transplantation.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Resistance; Drug Ther | 2002 |
Trials
5 trials available for adenine and Hepatitis C
Article | Year |
---|---|
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Vira | 2020 |
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatit | 2018 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; | 2013 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2014 |
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
Topics: Adenine; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Ma | 2006 |
Other Studies
26 other studies available for adenine and Hepatitis C
Article | Year |
---|---|
The making of the one pill-Developing single tablet regimens for HIV and for HCV.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Diso | 2022 |
Topics: Adenine; DEAD Box Protein 58; Hep G2 Cells; Hepatitis B; Hepatitis C; Humans; Immune Evasion; Immuni | 2020 |
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell T | 2018 |
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C; | 2013 |
WHO survey finds half of countries do not have clinical guidelines for treating hepatitis.
Topics: Adenine; Antiviral Agents; Drugs, Essential; Global Health; Guanine; Health Priorities; Hepatitis B; | 2013 |
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Kidney Diseases; Male; Oligop | 2014 |
Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
Topics: Adenine; Adult; Alleles; Antiviral Agents; Asian People; Case-Control Studies; Dinucleotide Repeats; | 2015 |
Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
Topics: Adenine; Adult; Antiviral Agents; Carrier State; Drug Therapy, Combination; Hepatitis B; Hepatitis B | 2008 |
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Comorbidity; Female; | 2010 |
Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.
Topics: Adenine; Animals; Animals, Outbred Strains; Antiviral Agents; Cell Line, Tumor; Hepacivirus; Hepatit | 2010 |
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort | 2010 |
Cystatin C and baseline renal function among HIV-infected persons in the SUN Study.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Cohort Studies; Cross-Sectio | 2012 |
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication.
Topics: Adenine; Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Organophosphonat | 2011 |
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combi | 2012 |
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
Topics: Adenine; Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; | 2012 |
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hep | 2013 |
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res | 2012 |
Sexually transmitted infection with an immune-escape mutant hepatitis B virus in an hepatitis B virus-vaccinated individual with acute HIV-hepatitis C virus infection.
Topics: Acute Disease; Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Deoxycytidine; Drug | 2013 |
Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Dr | 2002 |
Synthesis and biological evaluation of 2,8-disubstituted 9-benzyladenines: discovery of 8-mercaptoadenines as potent interferon-inducers.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; Drug Design; Gene Expression Regulation; Hepati | 2003 |
Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities.
Topics: Adenine; Administration, Oral; Aminoquinolines; Animals; Biological Availability; Cells, Cultured; D | 2004 |
[Viral hepatitis B/C and HIV. Therapy of double infections].
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as T | 2003 |
Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
Topics: Adenine; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B e Antigens; | 2005 |
Activation of anti-hepatitis C virus responses via Toll-like receptor 7.
Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; Female; Hepacivirus; Hepatitis C; Hepatocytes; | 2006 |
Hybridization-AT-tailing (HybrAT) method for sensitive and strand-specific detection of DNA and RNA.
Topics: Adenine; Base Sequence; DNA; DNA-Directed DNA Polymerase; Hepatitis C; Hepatitis C Antibodies; Human | 1998 |
Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients.
Topics: Adenine; Aged; Carcinoma, Hepatocellular; Codon; Cohort Studies; DNA, Viral; Exons; Female; Genes, p | 1998 |